Literature DB >> 8336307

Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis.

C Gabay1, P Roux-Lombard, P de Moerloose, J M Dayer, T Vischer, P A Guerne.   

Abstract

To investigate if the low C-reactive protein (CRP) response frequently observed in systemic lupus erythematosus (SLE) is related to an impaired expression of interleukin 6 (IL-6), considered its main inducer, we studied serum IL-6 and CRP levels in 37 patients with SLE and 22 with rheumatoid arthritis (RA). Results show that in contrast to CRP, IL-6 levels are significantly higher in SLE than in RA. A linear regression analysis shows a positive correlation between levels of these 2 molecules in RA but not in SLE. Similarly, levels of fibrinogen, another acute phase protein mainly induced by IL-6, did not correlate with IL-6 in SLE. Our results suggest an impairment of part of the acute phase response to IL-6 that might play a role in the pathogenesis of SLE.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8336307

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins.

Authors:  J K Lacki; W Samborski; S H Mackiewicz
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

Review 2.  A novel pathogenetic concept-antiviral immunity in lupus nephritis.

Authors:  Adriana Migliorini; Hans-Joachim Anders
Journal:  Nat Rev Nephrol       Date:  2012-01-17       Impact factor: 28.314

Review 3.  The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications.

Authors:  D A Horwitz; C O Jacob
Journal:  Springer Semin Immunopathol       Date:  1994

Review 4.  C-reactive protein in rheumatology: biology and genetics.

Authors:  Benjamin Rhodes; Barbara G Fürnrohr; Timothy J Vyse
Journal:  Nat Rev Rheumatol       Date:  2011-04-05       Impact factor: 20.543

5.  Interferon-α coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro.

Authors:  L Wirestam; H Enocsson; T Skogh; M L Eloranta; L Rönnblom; C Sjöwall; J Wetterö
Journal:  Clin Exp Immunol       Date:  2017-03-31       Impact factor: 4.330

6.  Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity.

Authors:  M W Boehme; U Raeth; P R Galle; W Stremmel; W A Scherbaum
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

7.  C-reactive protein (CRP) polymorphisms and haplotypes are associated with SLE susceptibility and activity but not with serum CRP levels in Mexican population.

Authors:  Yemil Atisha-Fregoso; Guadalupe Lima; Eduardo Carrillo-Maravilla; Rosalinda Posadas-Sánchez; Nonanzit Pérez-Hernández; Miguel Baños-Peláez; Alejandra Iturralde-Chávez; Nora Hernández-Díaz; Juan Jakez-Ocampo; José Manuel Rodríguez-Pérez; Gilberto Vargas-Alarcón; Luis Llorente; Juanita Romero-Díaz
Journal:  Clin Rheumatol       Date:  2018-03-20       Impact factor: 2.980

8.  Circulating concentrations of interleukin-6 in cancer patients and their pathogenic role in tumor-induced hypercalcemia.

Authors:  B Vanderschueren; J C Dumon; V Oleffe; C Heymans; J Gérain; J J Body
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

9.  Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease.

Authors:  M C Kinney; D S Hummell; P M Villiger; A Hourigan; L Rollins-Smith; A D Glick; A R Lawton
Journal:  J Clin Immunol       Date:  1994-11       Impact factor: 8.317

10.  IL-1 receptor antagonist (IL-1Ra) does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumour cells.

Authors:  C Gabay; B Genin; G Mentha; P B Iynedjian; P Roux-Lombard; P A Guerne
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.